Literature DB >> 1425875

Urinary caffeine metabolites in man. Age-dependent changes and pattern in various clinical situations.

D Ullrich1, D Compagnone, B Münch, A Brandes, H Hille, J Bircher.   

Abstract

In an exploratory study the 24-h urinary excretion pattern of caffeine and 14 of its major metabolites was studied in 32 volunteers (adults, adolescents and children), 14 patients either with end stage renal disease or liver cirrhosis, 7 heavy smokers and 27 patients on therapy with cimetidine, allopurinol, theophylline or phenytoin. Caffeine and its metabolites were quantified by UV-absorption after liquid/liquid-extraction and HPLC-separation, which ensured proper analysis of 1-methyluric acid. In adults the renal excretion of caffeine derivatives corresponded to an intake of 509 mg caffeine/day, with 1-methyluric acid as the predominant metabolite. About 69% of caffeine was degraded by the paraxanthine pathway, and theobromine- (19%) and the theophylline pathway (14%) were less important. The ratio of paraxanthine formation to urinary caffeine concentration (= clearance equivalent) was about 2.2 ml.min-1.kg-1 in adults, and the corresponding ratios for theophylline and theobromine were 0.43 ml.min-1.kg-1 and 0.59 ml.min-1.kg-1, respectively. As expected, caffeine degradation was impaired in patients with cirrhosis and was increased in persons who smoked heavily or who were on phenytoin therapy. The results document the possibility of noninvasively investigating gross differences in caffeine disposition by analysis of the urinary pattern of its metabolites.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1425875     DOI: 10.1007/bf01740665

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  41 in total

Review 1.  Nutrition and chemical biotransformations in man.

Authors:  A H Conney; E J Pantuck; R Kuntzman; A Kappas; K E Anderson; A P Alvares
Journal:  Clin Pharmacol Ther       Date:  1977-11       Impact factor: 6.875

2.  Comparison of the urinary metabolite profile of caffeine in young and elderly males.

Authors:  J Blanchard; S J Sawers; J H Jonkman; D D Tang-Liu
Journal:  Br J Clin Pharmacol       Date:  1985-02       Impact factor: 4.335

Review 3.  Caffeine and health.

Authors:  C H Ashton
Journal:  Br Med J (Clin Res Ed)       Date:  1987-11-21

4.  Differential effects of cimetidine on theophylline metabolic pathways.

Authors:  J J Grygiel; J O Miners; R Drew; D J Birkett
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

5.  Caffeine intakes of children from a biracial population: the Bogalusa Heart Study.

Authors:  M L Arbeit; T A Nicklas; G C Frank; L S Webber; M H Miner; G S Berenson
Journal:  J Am Diet Assoc       Date:  1988-04

6.  Comparison of theophylline and theobromine metabolism in man.

Authors:  D J Birkett; R Dahlqvist; J O Miners; A Lelo; B Billing
Journal:  Drug Metab Dispos       Date:  1985 Nov-Dec       Impact factor: 3.922

7.  A urinary metabolite ratio that reflects systemic caffeine clearance.

Authors:  M E Campbell; S P Spielberg; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1987-08       Impact factor: 6.875

8.  Nonlinear theophylline elimination.

Authors:  D D Tang-Liu; R L Williams; S Riegelman
Journal:  Clin Pharmacol Ther       Date:  1982-03       Impact factor: 6.875

9.  Paracetamol as a test drug to determine glucuronide formation in man. Effects of inducers and of smoking.

Authors:  K W Bock; J Wiltfang; R Blume; D Ullrich; J Bircher
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

10.  Caffeine disposition after oral doses.

Authors:  M Bonati; R Latini; F Galletti; J F Young; G Tognoni; S Garattini
Journal:  Clin Pharmacol Ther       Date:  1982-07       Impact factor: 6.875

View more
  6 in total

1.  An unusual patient with kidney stones composed of 1-methyluric acid.

Authors:  Phillip M Davies; Lynette D Fairbanks; Krzysztof Safranow; Michael R Bending; H Anne Simmonds
Journal:  Urol Res       Date:  2006-01-06

2.  Biotransformation of caffeine by cDNA-expressed human cytochromes P-450.

Authors:  H R Ha; J Chen; S Krahenbuhl; F Follath
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

3.  Nonparametric expectation maximisation (NPEM) population pharmacokinetic analysis of caffeine disposition from sparse data in adult caucasians: systemic caffeine clearance as a biomarker for cytochrome P450 1A2 activity.

Authors:  Dimiter Terziivanov; Kristina Bozhinova; Velislava Dimitrova; Ivanka Atanasova
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

4.  Caffeine prevents kidney stone formation by translocation of apical surface annexin A1 crystal-binding protein into cytoplasm: In vitro evidence.

Authors:  Paleerath Peerapen; Visith Thongboonkerd
Journal:  Sci Rep       Date:  2016-12-07       Impact factor: 4.379

5.  Pharmacokinetics of Caffeine following a Single Administration of Coffee Enema versus Oral Coffee Consumption in Healthy Male Subjects.

Authors:  Supanimit Teekachunhatean; Nisanuch Tosri; Noppamas Rojanasthien; Somdet Srichairatanakool; Chaichan Sangdee
Journal:  ISRN Pharmacol       Date:  2013-03-04

6.  Tea and coffee consumption in relation to vitamin D and calcium levels in Saudi adolescents.

Authors:  Abdulaziz Al-Othman; Sara Al-Musharaf; Nasser M Al-Daghri; Sobhy Yakout; Khalid M Alkharfy; Yousef Al-Saleh; Omar S Al-Attas; Majed S Alokail; Osama Moharram; Shaun Sabico; Sudhesh Kumar; George P Chrousos
Journal:  Nutr J       Date:  2012-08-20       Impact factor: 3.271

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.